Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
McKesson
Cantor Fitzgerald
UBS
McKinsey
Fish and Richardson

Generated: March 19, 2019

DrugPatentWatch Database Preview

King Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for KING PHARMS LLC, and when can generic versions of KING PHARMS LLC drugs launch?

KING PHARMS LLC has twelve approved drugs.

There is one US patent protecting KING PHARMS LLC drugs.

There are forty-five patent family members on KING PHARMS LLC drugs in thirty-two countries and four supplementary protection certificates in three countries.

Summary for King Pharms Llc
International Patents:45
US Patents:1
Tradenames:12
Ingredients:11
NDAs:12

Drugs and US Patents for King Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms Llc BICILLIN C-R 900/300 penicillin g benzathine; penicillin g procaine INJECTABLE;INJECTION 050138-003 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Sign Up ➤ Sign Up
King Pharms Llc INTAL cromolyn sodium SOLUTION;INHALATION 018596-001 May 28, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-003 Jan 28, 1991 AB RX Yes No 7,368,469 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for King Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc AVINZA morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021260-005 Dec 18, 2008 6,066,339 ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 5,403,856 ➤ Sign Up
King Pharms Llc INTAL cromolyn sodium SOLUTION;INHALATION 018596-001 May 28, 1982 3,777,033 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for KING PHARMS LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 45 mg and 75 mg ➤ Subscribe 2009-07-30
➤ Subscribe Extended-release Capsules 30 mg, 60 mg, 90 mg and 120 mg ➤ Subscribe 2007-06-04

Supplementary Protection Certificates for King Pharms Llc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0265685 C980030 Netherlands ➤ Sign Up PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
0265685 99C0001 Belgium ➤ Sign Up PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
0350733 SPC/GB03/034 United Kingdom ➤ Sign Up PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
US Department of Justice
Farmers Insurance
McKinsey
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.